A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.

doi:10.1007/BF03195700

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.

Journal of applied genetics - 1 Jan 2009

Stepien E, Branicka A, Ciesla-Dul M, Undas A

Abstract excerpt

A daily dose of vitamin K antagonists (VKAs) may vary and its range depends on various interrelated factors. Low responsiveness to VKA (defined as a failure to achieve a target international normalized ratio [INR]) is associated with polymorphisms of the vitamin K epoxide reductase-oxidase complex gene (VKORC1). A highly prevalent promoter single-nucleotide polymorphism (VKORC1-1639 G>A, rs17878363) impairs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Atrial Fibrillation

Share to International Normalized Ratio

Share to Pulmonary Embolism

Share to Venous Thrombosis

Share to Vitamin K

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Open in PubMed

Identifiers

PMID: 19875892
DOI: 10.1007/BF03195700

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.PMID 19875892Read ↗

The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy.Semantic proximity Read ↗

The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients.Semantic proximity Read ↗

[The c.-1639g > A polymorphism of the VKORC1 gene and his influence on the therapeutic response during oral anticoagulants use].Semantic proximity Read ↗

Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1.Semantic proximity Read ↗

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.Semantic proximity Read ↗

Genetic causes of resistance to vitamin K antagonists in Polish patients: a novel p.Ile123Met mutation in VKORC1 gene.Semantic proximity Read ↗

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.Semantic proximity Read ↗

Pharmacogenetics of warfarin: current status and future challenges.Semantic proximity Read ↗

A Pharmacogenetically Guided Acenocoumarol Dosing Algorithm for Chilean Patients: A Discovery Cohort StudySemantic proximity Read ↗

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].Semantic proximity Read ↗

Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.Semantic proximity Read ↗

[Oral anticoagulation and pharmacogenetics: importance in the clinical setting].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.